



FOR IMMEDIATE RELEASE

**Selexis SA to Present New Data on MARtech™ at the
BioProcess International, European Conference and Exhibition**

Data Will Elucidate the Mechanism Behind MARtech™

Geneva, Switzerland – February 13, 2006 – Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic protein manufacturing announced today that it will release new data from FISH analysis of CHO cell lines expressing recombinant proteins at the next BioProcess International, European Conference and Exhibition in Prague, Czech Republic (February 21-22, 2006).

Dr. Cori Gorman, Ph.D., M.B.A., will present these FISH data which will elucidate the mechanism behind MARtech™ on Tuesday, February 21, 2006 at 2:30 PM as part of the Cell Culture and Upstream Processing track. Selected slides from the lecture, including data on MARtech™, will also be available following the meeting.

Selexis' patented technology, MARtech™, improves the speed, yield and stability of production cell lines used for therapeutic protein manufacturing. MARtech™ allows fast cell population generation in 3 weeks (after transfection) and stable cell line development in 8 weeks (after transfection to first round of cell cloning). Additionally, MARtech™ has been found to increase recombinant protein expression in mammalian cells in suspension and in serum-free more than 10 fold.

About Selexis

Selexis is a privately held biotechnology company dedicated to the development of expert services and technologies for comprehensive and rapid solutions for stable, high yield cell line

- more -

SELEXIS EUROPE
18 chemin des Aulx
1228 Plan-les-Ouates
Switzerland

T +41 (0)22 308 93 60
F +41 (0)22 308 93 61

SELEXIS USA
655, Montgomery St. STE 540
San Francisco, CA 94111
USA

T +1 415 273 51 41
F +1 415 837 32 04

development and protein manufacturing for therapeutic drugs. The Company's unique seven step, high through put process, which includes the forth generation patented MARtech™, reduces traditional cell line development (DHFR) from 12 months to 3 months (after transfection to isolating cell clones) without any change in the scale-up process. For more information please visit <http://www.selexis.com>

About BioProcess International, European Conference and Exhibition

BioProcess International Conference and Exhibition is a collaboration between IBC's four successful biopharmaceutical development conferences and *BioProcess International*, the first and only international publication devoted to the development, scale-up, and manufacture of biotherapeutics and biodiagnostics. The conference is the premier event for a comprehensive update on operational strategies, technologies, regulatory changes, manufacturing production, and process development. The conference consists of four in-depth tracks: 1 - Scaling-up, Economics and Manufacturing Strategies; 2 - Formulation & Drug Delivery; 3 - Cell Culture & Upstream Processing; and 4 - Recovery & Purification. For more information, please visit <http://www.ibc-lifesci.com/bpi/2006>

This news release contains forward-looking statements that involve a number of known and unknown risks and uncertainties. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our business strategy will be successful or that we will be able to carry out our plans for 2007.

MARtech™ is a trademark of Selexis, SA.

MEDIA CONTACT:

Robert Meister
602-953-1716
robert.meister@selexis.com

MORE INFORMATION:

EUROPE
Igor Fisch, Ph.D.
41 (0)22 308 93 60
Igor.fisch@selexis.com

UNITED STATES
Cori Gorman, Ph.D., M.B.A.,
415-273-5141
cori.gorman@selexis.com